HIV incidence among injecting drug users in New York City syringe-exchange programmes

Lancet

Volumn 348, Issue 9033, 1996, Pages 987-991

  Des Jarlais, Don C ^a,c   Marmor, Michael ^b   Paone, Denise ^a   Titus, Stephen ^b   Shi, Qiuhu ^a   Perlis, Theresa ^c   Jose, Benny ^c   Friedman, Samuel R ^c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SYRINGE; UNITED STATES;

EID: 0242409954     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)02536-6     Document Type: Article

References (30)

1. 1 Des Jarlais DC, Stimson G, Hagan H, et al. Emerging infectious diseases and the injection of illicit drugs. Curr Iss Publ Hlth 1996; 2: 130-37.
2. 2 Lurie P, Reingold AL, Bowser B, et al. The public health impact of needle exchange programs in the United States and abroad, vol 1. Atlanta, Georgia: Centers for Disease Control and Prevention, September, 1993.
3. 3 Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press, 1995.
4. 4 Des Jarlais DC, Friedman SR. AIDS and legal access to sterile drug injection equipment. Ann Am Acad Political Soc Sci 1992; 521: 42-65.
5. 5 Des Jarlais DC. Current findings in syringe exchange research. London: UK Department of Health, 1994.
6. 6 Stimson GV. Syringe-exchange programmes for injecting drug users. AIDS 1989; 3: 253-60.
7. 7 US Government Accounting Office. Needle exchange programs: research suggests promise as an AIDS prevention strategy. Report to the Chairman, Select Commitee on Narcotics Abuse and Control. Washington, DC: US House of Representatives, 1993.
8. 8 Des Jarlais DC, Friedman SR, Novick D, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA 1989; 261: 1008-12.
9. 9 Anderson W. The New York needle trial: the politics of public health in the age of AIDS. Am J Publ Hlth 1991; 81: 1506-17.
10. 10 Paone D, Des Jarlais DC, Caloir S, Friedmann PB, Ness I, Friedman SR. New York City syringe exchange: an overview. In: proceedings: workshop on needle exchange and bleach distribution programs. Washington, DC: National Academy Press, 1994: 47-59.
11. 11 Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within a HIV epidemic: injecting drug users in New York City, 1984 through 1992. JAMA 1994; 271: 121-27.
12. 12 Cook TD, Cooper H, Cordray DS, et al. Meta-analysis for explanation: a casebook. New York: Russell Sage Foundation, 1994.
13. 13 Cooper H, Hedges LV, eds. The handbook of research synthesis. New York: Russell Sage Foundation, 1994.
14. 14 Spitzer WO, ed. The Potsdam international consultation on meta-analysis. J Clin Epidemiol 1995; 48: 1-172.
15. 15 Johnson AM, Parry JV, Best SJ, Smith AM, de Silva M, Mortimer PP. HIV surveillance by testing saliva. AIDS 1988; 2: 369-71.
16. 16 Marmor T, Titus S, Wolfe H, et al. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs. AIDS Res Human Retrovir 1994; 10 (suppl): 207S-13S.
17. 17 Brown BS, Beschner GM, eds (with The National AIDS Research Consortium). Handbook on risk of AIDS: injection drug users and sexual partners. Wesport, Connecticut: Greenwood Press, 1993.
18. 18 Friedman SR, Jose B, Deren S, et al. Risk factors for HIV seroconversion among out-of-treatment drug injectors in high-and-low seroprevalence cities. Am J Epidemiol 1995; 2: 864-74.
19. 19 Caussy D, Weiss SH, Blattner WA, et al. Exposure factors for HIV-1 infection among heterosexual drug abusers in New Jersey treatment programs. AIDS Res Hum Retrovir 1990; 6: 1459-67.
20. 20 D'Aquila RT, Peterson LR, Williams AB, Williams AE. Race/ethnicity as a risk factor for HIV-1 infection among Connecticut intravenous drug users. J AIDS 1989; 2: 503-13.
21. 21 Colon H. Travel patterns of Puerto Rican drug injectors: implications for the transmission and prevention of the Human Immunodeficiency Virus. Presented at the Conference on HIV/AIDS Epidemic in a Commuting Population: Puerto Ricans in New York City and Puerto Rico, Lehman College, Bronx, New York, November, 1992.
22. 22 Horsburgh C, Yih Ou C, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet 1989; 339: 637-40.
23. 23 Marmor M, Des Jarlias DC, Cohen H, et al. Risk factors for human immunodeficiency virus among intravenous drug users in New York City. AIDS 1987; 1: 39-44.
24. 24 SAS Institute. SAS/ST AT User's Guide. Cary, North Carolina: SAS Institute, 1993.
25. 25 Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1995.
26. 26 Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med 1985; 103: 755-59.
27. 27 Siddiqui NS, Brown LS Jr, Meyer TJ, Gonzalez V. Decline in HIV-1 seroprevalence and low seroconversion rates among injecting drug users at a Methadone Maintenance Program in New York City. J Psychoactive Drugs 1991; 25: 245-50.
28. 28 Orr MF, Friedman P, Glebatis D, Des Jarlais DC, Prevots DR. Incidence of HIV infection among clients of a methadone maintenance treatment program in New York City. JAMA (in press).
29. 29 Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Publ Hlth 1996; 86: 642-54.
30. 30 Neaigus A, Friedman SR, Jose B, Goldstein D, Curtis R, Des Jarlais DC. Latina race/ethnicity and injecting at outside settings are HIV risk factors among new injectors. Presented at an Annual American Public Health Association Conference, San Francisco, California, October 24-28 1993.